Chairman of the Board
Chief Medical Officer and Executive Vice-President, PanOptica, Inc.
Martin B. Wax, M.D., is chief medical officer and executive vice president of R&D at PanOptica, Inc., a private biotechnology company specializing in ophthalmic pharmaceuticals. He previously served as vice president of R&D and head of discovery research and preclinical sciences at Alcon Laboratories, where he was responsible for the creation and early development of the Alcon pharmaceutical portfolio.
Dr. Wax received his medical degree from the University of Southern California in Los Angeles. He completed his residency in Ophthalmology at Wills Eye Hospital in Pennsylvania, and post-doctoral fellowships in molecular pharmacology and glaucoma at the University of Pennsylvania School of Medicine.
He currently holds an appointment as a Professor of Ophthalmology and Visual Sciences at the University of Texas Southwestern Medical School in Dallas, and has been selected as one of the “Best Doctors in America” by his peers. An internationally recognized scientific expert in the field of glaucoma, Dr. Wax has co-authored more than 200 publications and serves on several scientific advisory committees and editorial boards.
Read More »
Mr. Kevin Giese was the founder of BioMS Medical Corp. which company raised over $280 million, and in 2008 was designated Biotech Company of the year in Canada and awarded the Scrips Award for Best International Licensing Deal.
Mr. Giese has been on the board of directors of a number of private and publicly listed companies, including Spectral Diagnostics Inc. since March 2010, and Mimetogen Pharmaceuticals Inc. since October 2011.
He has been a member of the board of directors of BioAlberta, an advisory member of the Institute of Corporate Directors (Canada) and has received awards for entrepreneurship from BioAlberta and Ernst & Young. Mr. Giese has a B.A., a law degree and an M.B.A.
See More »